(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.
----------
AIM - WINNERS
----------
Omega Diagnostics, up 40% at 96.98 pence, 12-month range 5.93p-126.95p. It will continue to modify its Alva-based facility to "upscale significantly" its lateral flow test production capacity as it noted a Financial Times article. The FT said the UK government has chosen three British companies to make rapid Covid-19 tests. The newspaper said Omega, SureScreen and Global Access Diagnostics have been selected by the Department of Health to produce up to 2 million lateral flow devices per day for the UK, according to two people briefed on the decision.
----------
Avacta Group, up 6.8% at 136.20 pence, 12-month range 13.00p-215.25p. Says it has entered into a commercial partnership with Mologic to accelerate to market Avacta's AffiDX SARS-CoV-2 lateral flow rapid antigen test. The pre-clinical stage biotechnology company said the partnership will provide the AffiDX antigen test a faster route to market by giving it a CE marking for professional use under rapid diagnostics firm Mologic's ISO13485 quality system.
----------
Tower Resources, up 11% at 0.56 pence, 12-month range 0.189p-0.650p. Notes its South African unit Rift Petroleum has received an updated resource at the offshore Algoa-Gamtoos license from partner New Age Energy Algoa. After reprocessing seismic data at the asset, overall portfolio volumes are 54% higher at Algoa-Gamtoos, Tower explained.
----------
AIM - LOSERS
----------
Bahamas Petroleum, down 67% at 0.68p, 12-month range 0.500p-5.722p. Bahamas said that while the Perseverance #1 well encountered hydrocarbons, commercial volumes of oil were not proven. The company said the Perseverance #1 well in the Bahamas encountered hydrocarbons, as well as successfully validating the structural model and the petroleum system. However, volumes of oil encountered "are not commercial".
----------
Tissue Regenix, down 12% at 0.65p, 12-month range 0.275p-1.280p. The company expects a revenue fall in 2020, citing the negative impact of the Covid-19 pandemic. The medical devices company expects revenue of GBP12.8 million, down 1.5% from 2019's GBP13.0 million. Its financial performance was "impacted by the ongoing coronavirus pandemic".
----------
Inland Homes, down 10% at 57.75p, 12-month range 32.00p-89.85p. The company reported a fall in full-year profit as activity was disrupted by the coronavirus pandemic. Its EPRA net asset value per share at the end of September 2020 was 103.97 pence per share, down 8.5% on a year ago due to a placing of 20.8 million new shares during the year. In a separate release, Inland Homes said Chair Terry Roydon will be standing down from the board at the conclusion of the company's annual general meeting in March. Senior Independent Director Simon Bennett will be promoted to chair,
----------
boohoo Group, down 4.5% at 348.40p, 12-month range 133.10p-433.50p. The AIM-listed online-only fashion retailer will be buying the e-commerce and digital assets and associated intellectual property rights, including customer data, related business information and inventory, of the Burton, Dorothy Perkins and Wallis brands. The GBP25.2 million deal to acquire the former Arcadia Group brands does not include any stores. boohoo said Monday's acquisition is a "significant opportunity to grow" its market share.
----------
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Tissue Regenix Group (TRX)
Avacta Group (AVCT)
Inland Zdp (INLZ)
Tower Resources (TRP)
Boohoo (BOO)